tert-butyl (2S)-2-[5-[4-[4-[(2S,8S,9R)-8-(methoxycarbonylamino)-9-methyl-7-oxo-10,15-dioxa-6,19,20-triazatricyclo[15.2.1.02,6]icosa-1(19),17-dien-18-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate | 1319190-40-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl (2S)-2-[5-[4-[4-[(2S,8S,9R)-8-(methoxycarbonylamino)-9-methyl-7-oxo-10,15-dioxa-6,19,20-triazatricyclo[15.2.1.02,6]icosa-1(19),17-dien-18-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carboxylate
• CAS: 1319190-40-3
• 化学式: C₄₂H₅₃N₇O₇
• 分子量: 767.926
• InChiKey: RLAAEASLOKWLBK-AVSSONEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  56
• 可旋转键数：
  8
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  164
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110189129A1

  公开（公告）日：2011-08-04

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—W  (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• Hepatitis C Virus Inhibitors
  申请人：Qiu Yao-Ling

  公开号：US20120076755A1

  公开（公告）日：2012-03-29

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W  (I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US8785487B2
  申请人：——

  公开号：US8785487B2

  公开（公告）日：2014-07-22
• US8933110B2
  申请人：——

  公开号：US8933110B2

  公开（公告）日：2015-01-13